Phase I/II study of Hyper-CVAD plus RAD001 (everolimus) for patients with relapsed or refractory acute lymphocytic leukemia.
Phase of Trial: Phase I/II
Latest Information Update: 02 Jun 2018
At a glance
- Drugs Everolimus (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Methotrexate; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 08 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 May 2015 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
- 10 May 2015 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History